http://rdf.ncbi.nlm.nih.gov/pubchem/patent/JP-2013234195-A

Outgoing Links

Predicate Object
assignee http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_938a6d7a15cbc93a74abe1953eb25d47
classificationCPCAdditional http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C12N2770-24222
classificationCPCInventive http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P31-12
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P31-16
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K31-191
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P31-14
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P43-00
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07D403-12
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K38-06
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K31-375
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P1-16
classificationIPCInventive http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K38-00
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C07C65-10
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C07C229-64
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C07K7-06
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C07C227-42
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61P43-00
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C07C51-43
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61P31-12
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C07C55-06
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61P31-16
filingDate 2013-07-26-04:00^^<http://www.w3.org/2001/XMLSchema#date>
inventor http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_60d42329a3a0351f14c2b9a5455dd7a5
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_32e7026fcdf1aaba91dba28e958988a4
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_00d9d6c02b9d16abbeda399ad3598b38
publicationDate 2013-11-21-04:00^^<http://www.w3.org/2001/XMLSchema#date>
publicationNumber JP-2013234195-A
titleOfInvention Co-crystal containing VX-950 and pharmaceutical composition containing the same
abstract A more effective anti-HCV treatment is provided. The present invention relates to compositions and co-crystals each comprising VX-950 and a co-crystal former selected from the group consisting of salicylic acid, 4-aminosalicylic acid and oxalic acid. Moreover, the manufacturing method and the usage method are also within the scope of the present invention. [Selection figure] None
priorityDate 2006-02-27-04:00^^<http://www.w3.org/2001/XMLSchema#date>
type http://data.epo.org/linked-data/def/patent/Publication

Incoming Links

Predicate Subject
isDiscussedBy http://rdf.ncbi.nlm.nih.gov/pubchem/substance/SID226394773
http://rdf.ncbi.nlm.nih.gov/pubchem/substance/SID226394558
http://rdf.ncbi.nlm.nih.gov/pubchem/compound/CID338
http://rdf.ncbi.nlm.nih.gov/pubchem/compound/CID4649

Total number of triples: 35.